Advanced in Neurotoxicity Syndromes

Dr. Nirav N. Shah

General Practice
2175 Quarry Rd, 
Bronx, NY 
Advanced in Neurotoxicity Syndromes
2175 Quarry Rd, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nirav Shah is a primary care provider, practicing in General Practice in Bronx, New York. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Hip Replacement, and Kidney Transplant.

His clinical research consists of co-authoring 244 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Neurotoxicity Syndromes.

Specialties
General Practice
Licenses
General Practice in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2175 Quarry Rd, Bronx, NY 10457

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
Enrollment Status: Terminated
Publish Date: November 13, 2025
Intervention Type: Drug
Study Drug: Fenretinide
Study Phase: Phase 2/Phase 3
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug, Biological
Study Drugs: YTB323, Ibrutinib
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase II, Single-Arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Chimeric Antigen Receptor T-Cell Therapy, Zanubrutinib
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
View 7 Less Clinical Trials

244 Total Publications

Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response.
Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Similar Doctors
Experienced in Neurotoxicity Syndromes
Dr. Xin H. He
General Practice
Experienced in Neurotoxicity Syndromes
Dr. Xin H. He
General Practice
60 W 75th St Lowr Level, 
New York, NY 
 (7.2 miles away)
646-662-2908
Languages Spoken:
English

Xin He is a primary care provider, practicing in General Practice in New York, New York. Dr. He is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. Her top areas of expertise are Ruvalcaba Syndrome, Lhermitte-Duclos Disease, Bannayan-Riley-Ruvalcaba Syndrome, Vertebroplasty, and Thalamotomy.

Experienced in Neurotoxicity Syndromes
Dr. David Tavdy
Internal Medicine | General Practice
Experienced in Neurotoxicity Syndromes
Dr. David Tavdy
Internal Medicine | General Practice
11045 Queens Boulevard, Suite 104, 
Forest Hills, NY 
 (9.6 miles away)
718-261-2992
Languages Spoken:
English, Georgian, Russian
See accepted insurances

David Tavdy is a primary care provider, practicing in Internal Medicine and General Practice in Forest Hills, New York. Dr. Tavdy is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Maturity Onset Diabetes of the Young, Sepsis, Movement Disorders, Gastrostomy, and Colonoscopy.

Experienced in Neurotoxicity Syndromes
Dr. Dewitt Pyburn
General Practice
Experienced in Neurotoxicity Syndromes
Dr. Dewitt Pyburn
General Practice

Icahn School Of Medicine At Mount Sinai

1000 10th Ave, 
New York, NY 
 (7.7 miles away)
212-523-6521
Languages Spoken:
English
See accepted insurances

Dewitt Pyburn is a primary care provider, practicing in General Practice in New York, New York. Dr. Pyburn is rated as an Advanced provider by MediFind in the treatment of Neurotoxicity Syndromes. His top areas of expertise are Encephalitis, Anti-NMDA Receptor Encephalitis, Rasmussen Encephalitis, Generalized Tonic-Clonic Seizure, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile